Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
Recruiting
Phase 3
Interventional Study
Acute Ischemic Stroke
Atrial Fibrillation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 1,746 (estimated)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis
* Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable
* AF first detected ≤1 year prior to randomization
* Informed …
Contacts